Amylyx Pharmaceuticals
AMLX
27.43
-0.61
-2.18%
Amylyx Pharmaceuticals
US · AMLX
#2392 by market cap
Listed 2022
27.43
-0.61
-2.18%
Live - 5344 symbols - heartbeat 116s ago
· 2026-10-07 19:58
After-hours
27.43
0.00%
- Market cap
- 3.44B
- P/E (TTM)i
- -19.45
- P/Bi
- 14.39
- EPSi
- -1.53
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on AMLX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
45.75 +66.8%
Price target rangecurrent 27.43
Low32.00
Avg45.75
High57.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | Stifel | -- | BUY | 45.00 |
| 2026-08-26 | Guggenheim | -- | BUY | 57.00 |
| 2026-08-22 | LifeSci Capital | -- | BUY | 44.00 |
| 2026-08-20 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-08-19 | Mizuho Securities | -- | BUY | 42.00 |
| 2026-08-19 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-08-18 | TD Cowen | -- | BUY | -- |
| 2026-08-18 | LifeSci Capital | -- | BUY | 44.00 |
| 2026-08-18 | Mizuho Securities | -- | BUY | 42.00 |
| 2026-08-18 | BofA Securities | -- | BUY | 39.00 |
| 2026-08-18 | Baird | -- | BUY | 52.00 |
| 2026-08-18 | Stifel | -- | BUY | -- |
| 2026-08-18 | Citi | -- | BUY | 32.00 |
| 2026-08-18 | Guggenheim | -- | BUY | 55.00 |
| 2026-08-18 | H.C. Wainwright | -- | BUY | 55.00 |
| 2026-08-17 | Mizuho Securities | -- | BUY | 30.00 |
| 2026-08-07 | Baird | -- | BUY | 28.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-08-06 | TD Cowen | -- | BUY | -- |
| 2026-08-06 | LifeSci Capital | -- | BUY | 24.00 |
| 2026-08-04 | Citi | -- | BUY | 26.00 |
| 2026-08-03 | Citi | -- | BUY | 26.00 |
| 2026-07-30 | LifeSci Capital | -- | BUY | 24.00 |
| 2026-07-20 | Mizuho Securities | -- | BUY | 24.00 |
| 2026-07-01 | H.C. Wainwright | -- | BUY | 34.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | -- | ±29.34% | +10.71% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±9.74% | -5.35% (in line) |
| 2025/Q4 | 2026-03-03 | -- | ±19.28% | -7.78% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±18.20% | -5.89% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±18.78% | -4.27% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±26.63% | -5.95% (in line) |
| 2024/Q4 | 2025-03-04 | -- | ±21.67% | +0.33% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±17.35% | +5.14% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±24.20% | -4.26% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±15.03% | -2.07% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±24.55% | +21.10% (in line) |
| 2023/Q3 | 2023-11-09 | -- | ±13.90% | -31.89% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-07 19:58:32 · For reference only, not investment advice and not tailored to your situation.